EUVIMEDEUVIMED entdecken
Crossref

Novel agonist monoclonal antibody targeting GPCR to decrease neutrophil accumulation and initiate resolution of chronic inflammation 2310040

Charles-Antoine Coupet, Charlène Trilleaud, Julien Taurelle, Clémence Gaudin, Margaux Seite, Amandine Georges, Geraldine Teppaz, Antoine Arvor, Cecile Batty, Martin Lecomte, Ariane Desselle, Marine Malloci und 7 weitere

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.1677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Charles-Antoine Coupet und 18 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Resolution of inflammation is an active process mediated by specialized receptors such GPCRs expressed on neutrophils, monocytes, and macrophages. Natural and synthetic GPCRs agonists demonstrate significant preclinical efficacy but face limitations in stability, synthesis, and receptor selectivity.

Methods

New antibodies were generated and characterized for high affinity and GPCR specificity. Agonist signaling and activity was assessed on cell lines and primary neutrophils and monocytes, and efficacy was evaluated in multiple clinically relevant murine models of acute and chronic inflammation.

Results

We developed first-in-class antibodies acting as a selective GPCR agonist for the treatment of acute and chronic inflammatory diseases with stable properties and selectivity. This therapy allows a specific agonistic signal and promotes the hallmark pro-resolving activity by limiting activation and recruitment of neutrophils and monocytes/macrophages in contrast to natural or synthetic lipids that can trigger both pro- and anti-inflammatory signals in multiple GPCRs. In an acute lung injury model, the mAb markedly inhibits neutrophils and inflammatory monocytes infiltration into inflamed tissue. In chronic models, treatment alleviates clinical severity, confirming robust therapeutic potential.

Conclusion

This first-in-class GPCR specific agonist mAb introduces a novel strategy to actively drive long term resolution of inflammation. Its receptor specificity, strict agonist activity and robust preclinical efficacy on neutrophils and inflammatory monocytes recruitment position it as a promising therapeutic candidate for treating acute and chronic inflammatory disorders. Funding Source n/a Topic Categories Cellular Adhesion, Migration, and Inflammation (CAM)

Zitieren

APA

Coupet, C., Trilleaud, C., Taurelle, J., Gaudin, C., Seite, M., Georges, A., Teppaz, G., Arvor, A., Batty, C., Lecomte, M., Desselle, A., Malloci, M., Biteau, K., Foucher, E., Girault, I., Mary, C., Gauttier, V., Morello, A., & Poirier, N. (2026). Novel agonist monoclonal antibody targeting GPCR to decrease neutrophil accumulation and initiate resolution of chronic inflammation 2310040. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1677

Vancouver

Coupet C, Trilleaud C, Taurelle J, Gaudin C, Seite M, Georges A, et al. Novel agonist monoclonal antibody targeting GPCR to decrease neutrophil accumulation and initiate resolution of chronic inflammation 2310040. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1677

BibTeX
@article{Coupet2026,
  author = {Coupet, Charles-Antoine and Trilleaud, Charlène and Taurelle, Julien and Gaudin, Clémence and Seite, Margaux and Georges, Amandine and Teppaz, Geraldine and Arvor, Antoine and Batty, Cecile and Lecomte, Martin and Desselle, Ariane and Malloci, Marine and Biteau, Kevin and Foucher, Etienne and Girault, Isabelle and Mary, Caroline and Gauttier, Vanessa and Morello, Aurore and Poirier, Nicolas},
  title = {Novel agonist monoclonal antibody targeting GPCR to decrease neutrophil accumulation and initiate resolution of chronic inflammation 2310040},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.1677}
}
Kostenlos starten →